Lun–Xiu Qin

21.8k total citations · 8 hit papers
236 papers, 14.7k citations indexed

About

Lun–Xiu Qin is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Lun–Xiu Qin has authored 236 papers receiving a total of 14.7k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Molecular Biology, 101 papers in Cancer Research and 67 papers in Oncology. Recurrent topics in Lun–Xiu Qin's work include Hepatocellular Carcinoma Treatment and Prognosis (58 papers), Cancer, Hypoxia, and Metabolism (40 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (35 papers). Lun–Xiu Qin is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (58 papers), Cancer, Hypoxia, and Metabolism (40 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (35 papers). Lun–Xiu Qin collaborates with scholars based in China, United States and Germany. Lun–Xiu Qin's co-authors include Zhao–You Tang, Hu‐Liang Jia, Qing‐Hai Ye, Qiongzhu Dong, Hui‐Chuan Sun, Xin Wei Wang, Anuradha Budhu, Marshonna Forgues, Jia Fan and Ning Ren and has published in prestigious journals such as Nature Communications, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Lun–Xiu Qin

230 papers receiving 14.5k citations

Hit Papers

EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-I... 2008 2026 2014 2020 2008 2011 2008 2008 2020 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell Features
    2008 958 citations Taro Yamashita, Junfang Ji et al. Gastroenterology profile →
  2. Identification of miRNomes in Human Liver and Hepatocellular Carcinoma Reveals miR-199a/b-3p as Therapeutic Target for Hepatocellular Carcinoma
    2011 600 citations Qiongzhu Dong, Lun–Xiu Qin et al. profile →
  3. EpCAM and α-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
    2008 577 citations Taro Yamashita, Marshonna Forgues et al. Cancer Research profile →
  4. Identification of metastasis-related microRNAs in hepatocellular carcinoma
    2008 574 citations Anuradha Budhu, Hu‐Liang Jia et al. Hepatology profile →
  5. Isolation and characterization of exosomes for cancer research
    2020 376 citations Haoting Sun, Yan Zheng et al. profile →
  6. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives
    2021 220 citations Yan Zheng, Lun–Xiu Qin et al. profile →
  7. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC
    2021 212 citations Jubo Zhang, Wenwei Zhu et al. Hepatology profile →
  8. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives
    2024 82 citations Sun‐Zhe Xie, Lun–Xiu Qin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lun–Xiu Qin China 65 7.8k 6.3k 3.8k 3.5k 1.9k 236 14.7k
Zhao–You Tang China 63 6.5k 0.8× 5.2k 0.8× 4.1k 1.1× 5.2k 1.5× 2.8k 1.4× 209 14.8k
Hui‐Chuan Sun China 58 5.0k 0.6× 4.2k 0.7× 3.1k 0.8× 3.7k 1.1× 2.0k 1.0× 308 11.8k
Hiroaki Nagano Japan 60 5.0k 0.6× 3.2k 0.5× 4.2k 1.1× 3.5k 1.0× 2.2k 1.1× 451 13.1k
Mengchao Wu China 59 4.8k 0.6× 3.8k 0.6× 3.7k 1.0× 5.2k 1.5× 3.3k 1.7× 312 13.7k
Terence K. Lee Hong Kong 59 6.3k 0.8× 3.5k 0.6× 4.3k 1.1× 1.9k 0.5× 876 0.5× 170 10.8k
Shigeki Arii Japan 60 5.4k 0.7× 3.4k 0.5× 3.4k 0.9× 6.5k 1.9× 3.7k 1.9× 307 14.4k
Taro Yamashita Japan 46 4.5k 0.6× 2.9k 0.5× 2.8k 0.7× 2.7k 0.8× 1.8k 0.9× 240 9.4k
Lars Zender Germany 51 10.0k 1.3× 4.1k 0.7× 3.6k 0.9× 1.2k 0.3× 1.5k 0.8× 164 15.8k
Paulette Bioulac‐Sage France 62 6.2k 0.8× 3.5k 0.5× 3.4k 0.9× 7.2k 2.1× 4.7k 2.5× 353 16.9k
Charles Balabaud France 55 4.7k 0.6× 2.5k 0.4× 2.4k 0.6× 5.6k 1.6× 3.5k 1.8× 238 12.5k

Countries citing papers authored by Lun–Xiu Qin

Since Specialization
Citations

This map shows the geographic impact of Lun–Xiu Qin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lun–Xiu Qin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lun–Xiu Qin more than expected).

Fields of papers citing papers by Lun–Xiu Qin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lun–Xiu Qin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lun–Xiu Qin. The network helps show where Lun–Xiu Qin may publish in the future.

Co-authorship network of co-authors of Lun–Xiu Qin

This figure shows the co-authorship network connecting the top 25 collaborators of Lun–Xiu Qin. A scholar is included among the top collaborators of Lun–Xiu Qin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lun–Xiu Qin. Lun–Xiu Qin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xu, Hao, Sun‐Zhe Xie, Yinghan Su, et al.. (2025). Comparison of 11C‐Acetate and 18F‐FDG PET/CT for Immune Infiltration and Prognosis in Hepatocellular Carcinoma. Cancer Science. 116(4). 990–1003.
2.
Qin, Lun–Xiu, et al.. (2025). Dietary content and eating behavior in ulcerative colitis: a narrative review and future perspective. Nutrition Journal. 24(1). 12–12. 2 indexed citations
3.
Li, Yingxue, Haoting Sun, Zhenzhong Guo, et al.. (2025). Spatial Transcriptomics and snRNA‐seq Expose CAF Niches Orchestrating Dual Stromal‐Immune Barriers in Hepatocellular Carcinoma. Advanced Science. 12(48). e14661–e14661.
4.
Yang, Luyu, Xiaotian Shen, Junjie Pan, et al.. (2024). Targeting Gsk3a reverses immune evasion to enhance immunotherapy in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 12(8). e009642–e009642. 8 indexed citations
5.
Yang, Xin, Lu Lu, Wenwei Zhu, et al.. (2023). Ex vivo liver resection and auto-transplantation as an alternative for the treatment of liver malignancies: Progress and challenges. Hepatobiliary & pancreatic diseases international. 23(2). 117–122. 6 indexed citations
6.
7.
Takai, Atsushi, Hien Dang, Naoki Oishi, et al.. (2019). Genome-Wide RNAi Screen Identifies PMPCB as a Therapeutic Vulnerability in EpCAM+ Hepatocellular Carcinoma. Cancer Research. 79(9). 2379–2391. 23 indexed citations
8.
Dong, Qiongzhu, Yi Du, Hui Li, et al.. (2018). EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma. Cancer Research. 79(4). 819–829. 59 indexed citations
9.
Zhu, Wenwei, Lei Guo, Hu‐Liang Jia, et al.. (2013). Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma. Clinical Cancer Research. 19(14). 3944–3954. 111 indexed citations
10.
Zhou, Chuang, Haijun Zhou, Xiaofei Zhang, et al.. (2012). Postoperative Serum Osteopontin Level is a Novel Monitor for Treatment Response and Tumor Recurrence after Resection of Hepatitis B–related Hepatocellular Carcinoma. Annals of Surgical Oncology. 20(3). 929–937. 23 indexed citations
11.
Dong, Qiongzhu, Yue Zhao, Hu‐Liang Jia, et al.. (2012). Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma. Hepatology. 57(3). 1024–1034. 55 indexed citations
12.
Ren, Ning, Jincai Wu, Qiongzhu Dong, et al.. (2011). Association of Specific Genotypes in Metastatic Suppressor HTPAP with Tumor Metastasis and Clinical Prognosis in Hepatocellular Carcinoma. Cancer Research. 71(9). 3278–3286. 17 indexed citations
13.
Roessler, Stéphanie, Anuradha Budhu, Yidong Chen, et al.. (2011). Integrative Genomic Identification of Genes on 8p Associated With Hepatocellular Carcinoma Progression and Patient Survival. Gastroenterology. 142(4). 957–966.e12. 248 indexed citations
14.
Xiong, Yuquan, Hui‐Chuan Sun, Wei Zhang, et al.. (2009). Human Hepatocellular Carcinoma Tumor–derived Endothelial Cells Manifest Increased Angiogenesis Capability and Drug Resistance Compared with Normal Endothelial Cells. Clinical Cancer Research. 15(15). 4838–4846. 172 indexed citations
15.
Fan, Jia, Zhi-Quan Wu, Xin‐Da Zhou, et al.. (2009). Surgical treatment of primary hepatocellular carcinoma: a 20-year clinical experience in 7566 patients.. Zhōnghuá xiāohuà wàikē zázhì/Zhonghua xiaohua waike zazhi. 8(2). 99–102. 1 indexed citations
16.
Yamashita, Taro, Marshonna Forgues, Wei Wang, et al.. (2008). EpCAM and α-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma. Cancer Research. 68(5). 1451–1461. 577 indexed citations breakdown →
17.
Yamashita, Taro, Junfang Ji, Anuradha Budhu, et al.. (2008). EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell Features. Gastroenterology. 136(3). 1012–1024.e4. 958 indexed citations breakdown →
18.
Jia, Hu‐Liang, Qing‐Hai Ye, Lun–Xiu Qin, et al.. (2007). Gene Expression Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma. Clinical Cancer Research. 13(4). 1133–1139. 169 indexed citations
19.
Zhang, Hui, Qing‐Hai Ye, Ning Ren, et al.. (2006). The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology. 132(11). 709–717. 72 indexed citations
20.
Sun, Hui‐Chuan, Zhao–You Tang, Zeng‐Chen Ma, et al.. (2005). The prognostic factor for outcome following second resection for intrahepatic recurrence of hepatocellular carcinoma with a hepatitis B virus infection background. Journal of Cancer Research and Clinical Oncology. 131(5). 284–288. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhao–You Tang Breakdown of academic impact, for papers by Hui‐Chuan Sun Breakdown of academic impact, for papers by Hiroaki Nagano Breakdown of academic impact, for papers by Mengchao Wu Breakdown of academic impact, for papers by Terence K. Lee Breakdown of academic impact, for papers by Shigeki Arii Breakdown of academic impact, for papers by Taro Yamashita Breakdown of academic impact, for papers by Lars Zender Breakdown of academic impact, for papers by Paulette Bioulac‐Sage Breakdown of academic impact, for papers by Charles Balabaud
Rankless by CCL
2026